269 related articles for article (PubMed ID: 25949875)
1. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
Li J; Chen QY; He J; Li ZL; Tang XF; Chen SP; Xie CM; Li YQ; Huang LX; Ye SB; Ke M; Tang LQ; Liu H; Zhang L; Guo SS; Xia JC; Zhang XS; Zheng LM; Guo X; Qian CN; Mai HQ; Zeng YX
Oncoimmunology; 2015 Feb; 4(2):e976507. PubMed ID: 25949875
[TBL] [Abstract][Full Text] [Related]
2. A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients.
Liang YJ; Chen QY; Xu JX; Liu XF; Xia JC; Liu LT; Guo SS; Song B; Wang P; Li JB; Liu Q; Mo HY; Guo L; Sun R; Luo DH; He J; Liu YN; Nie CP; Tang LQ; Li J; Mai HQ
Eur J Cancer; 2023 Sep; 191():112965. PubMed ID: 37540921
[TBL] [Abstract][Full Text] [Related]
3. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
4. Clonal dynamics of tumor-infiltrating T-cell receptor beta-chain repertoires in the peripheral blood in response to concurrent chemoradiotherapy for Epstein-Barr virus-associated nasopharyngeal carcinoma.
Chung YL; Wu ML
Oncoimmunology; 2021; 10(1):1968172. PubMed ID: 34513316
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy.
He J; Tang XF; Chen QY; Mai HQ; Huang ZF; Li J; Zeng YX
Chin J Cancer; 2012 Jun; 31(6):287-94. PubMed ID: 22257383
[TBL] [Abstract][Full Text] [Related]
7. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.
Li J; Zhang XS; Xie D; Deng HX; Gao YF; Chen QY; Huang WL; Masucci MG; Zeng YX
Cancer Biol Ther; 2007 Dec; 6(12):1997-2004. PubMed ID: 18087217
[TBL] [Abstract][Full Text] [Related]
8. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
Comoli P; De Palma R; Siena S; Nocera A; Basso S; Del Galdo F; Schiavo R; Carminati O; Tagliamacco A; Abbate GF; Locatelli F; Maccario R; Pedrazzoli P
Ann Oncol; 2004 Jan; 15(1):113-7. PubMed ID: 14679129
[TBL] [Abstract][Full Text] [Related]
9. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
Louis CU; Straathof K; Bollard CM; Ennamuri S; Gerken C; Lopez TT; Huls MH; Sheehan A; Wu MF; Liu H; Gee A; Brenner MK; Rooney CM; Heslop HE; Gottschalk S
J Immunother; 2010; 33(9):983-90. PubMed ID: 20948438
[TBL] [Abstract][Full Text] [Related]
10. Five-year disease-free survival of Epstein-Barr virus-associated locoregionally advanced undifferentiated nasopharyngeal carcinoma patients treated with chemo-radiotherapy: a case report.
Wang N; Wang H; Jiang H; Bi Y; Zhao Y; He X; Cao F; Yuan Y
Ann Palliat Med; 2022 Mar; 11(3):1147-1152. PubMed ID: 35365045
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
[TBL] [Abstract][Full Text] [Related]
12. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
Huang H; Nie CP; Liu XF; Song B; Yue JH; Xu JX; He J; Li K; Feng YL; Wan T; Zheng M; Zhang YN; Ye WJ; Li JD; Li YF; Li JY; Cao XP; Liu ZM; Zhang XS; Liu Q; Zhang X; Liu JH; Li J
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35727633
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
15. The Safety and Immunological Effects of rAd5-EBV-LMP2 Vaccine in Nasopharyngeal Carcinoma Patients: A Phase I Clinical Trial and Two-Year Follow-Up.
Si Y; Deng Z; Lan G; Du H; Wang Y; Si J; Wei J; Weng J; Qin Y; Huang B; Yang Y; Qin Y
Chem Pharm Bull (Tokyo); 2016; 64(8):1118-23. PubMed ID: 27477649
[TBL] [Abstract][Full Text] [Related]
16. Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer.
Lee AZE; Tan LSY; Lim CM
Oral Oncol; 2018 Sep; 84():61-70. PubMed ID: 30115477
[TBL] [Abstract][Full Text] [Related]
17. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.
Lin MC; Lin YC; Chen ST; Young TH; Lou PJ
BMC Cancer; 2017 Jan; 17(1):18. PubMed ID: 28056887
[TBL] [Abstract][Full Text] [Related]
19. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy.
Li J; Zeng XH; Mo HY; Rolén U; Gao YF; Zhang XS; Chen QY; Zhang L; Zeng MS; Li MZ; Huang WL; Wang XN; Zeng YX; Masucci MG
PLoS One; 2007 Nov; 2(11):e1122. PubMed ID: 17987110
[TBL] [Abstract][Full Text] [Related]
20. T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results.
Secondino S; Zecca M; Licitra L; Gurrado A; Schiavetto I; Bossi P; Locati L; Schiavo R; Basso S; Baldanti F; Maccario R; Locatelli F; Siena S; Pedrazzoli P; Comoli P
Ann Oncol; 2012 Feb; 23(2):435-41. PubMed ID: 21586688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
